MXCT Company Profile and Key Details

MXCT has shown weak momentum, losing -11.03% over the past week and -24.84% over the past quarter, though year-to-date performance is down -21.94%. Short-term trend indicators are bullishly aligned (SMA20 0.42%, SMA50 -31.56%, SMA200 -51.78%). The stock’s 14-day RSI is 35.05 (weak momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.52% below its high and over 23.19% above its low. Average 10-day trading volume of 1.20 million shares is in line with the 3-month average of 1.27 million, indicating normal recent market interest.

MaxCyte, Inc. generated EPS of -$0.43 over the past year. Five-year average earnings growth is -11.37%. Wall Street analysts project EPS growth of 14.43% annually over the next five years. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.08. Next year's EPS is expected at -$6.12. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $6.00. The high target offers 1084.21% upside. The low target suggests 689.47% downside. The mean target is $7.50. This offers 886.84% upside. MaxCyte, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 18.91%. The prior quarter beat by 20.0%. Over the last six quarters, Apple has recorded several small beats. These include -35.71% in August 06, 2024.

MaxCyte, Inc. has 106.67 million shares outstanding. The public float is 105.17 million shares, elevated short interest at 4.80% of float. This equals 5.09 million shares. The short ratio is 3.69 days. Institutional investors hold 76.77% of the float. Insiders own 1.77%. Casdin Partners Master Fund, L.P. holds 10.00 million shares, Casdin Eli has 10.00 million shares and Erck Stanley C has 398.33 thousand shares.

MaxCyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

MaxCyte, Inc. (NASDAQ:MXCT) closed at $0.84 USD, gaining $0.07 (8.89%) from the previous close of $0.77. The stock is currently mid-range between its 52-week high and low $0.64 and $3.58. With a market capitalization of about $89.14 million, MaxCyte, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.43). Key stats such as the average daily volume over the past year has been around 1.06 million shares, trading with heavier-than-usual volume. Headquartered in Rockville, MD, MaxCyte, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Maher Masoud, the company employs approximately 114 people and listed since July 30, 2021. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.

Our AI price prediction model suggests that MaxCyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.24%, with price expected at $0.80 by March 17, 2026, within a range of $0.74 to $0.86 3-Month Outlook: Projected fall of -46.07%, reaching $0.41 by June 01, 2026, with a range of $0.34 to $0.49. 1-Year Outlook: Projected loss of -30.28%, with price at $0.53 by March 03, 2027, within a range of $0.00 to $0.00.

MaxCyte, Inc. (NASDAQ:MXCT) shares are down -21.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MaxCyte, Inc. trading at a premium to the broader market with a P/E of -1.81. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $9.20, suggesting 1110.21% upside. Our AI forecast model points to short-term strength (5.24% over two weeks), a medium-term fall (-46.07% over three months), and a longer-term loss (-30.28% over one year), with expected trading ranges indicating moderate volatility.

MaxCyte, Inc. trades at a P/E ratio of -1.81, slightly below the S&P 500 average, with a price-to-sales ratio of 2.4 and a price-to-book ratio of 0.46 suggesting the stock is closer to book value. The P/FCF stands at -2.01, also above market averages.